TIGIT predominantly regulates the immune response via regulatory T cells. - Wikidata - wikimedia - TriplyDB

TIGIT predominantly regulates the immune response via regulatory T cells.

TIGIT predominantly regulates the immune response via regulatory T cells.

http://www.wikidata.org/entity/Q36266506

about

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.Peripherally Induced Regulatory T Cells: Recruited Protectors of the Central Nervous System against Autoimmune Neuroinflammation.Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016 Tim-3 and its role in regulating anti-tumor immunity.Meta-Analysis of Parkinson's Disease Transcriptome Data Using TRAM Software: Whole Substantia Nigra Tissue and Single Dopamine Neuron Differential Gene Expression.Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity Interruption of OX40L signaling prevents costimulation blockade-resistant allograft rejection.TIGIT and Helios Are Highly Expressed on CD4+ T Cells in Sézary Syndrome Patients.Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Reversing T-cell Dysfunction and Exhaustion in Cancer.Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.Immune checkpoints and their inhibition in cancer and infectious diseases.Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?Immune checkpoint inhibitors for cancer treatment.The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation.TIGIT signalling pathway negatively regulates CD4+ T-cell responses in systemic lupus erythematosus.Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.CD14+ Cells with the Phenotype of Infiltrated Monocytes Consist of Distinct Populations Characterized by Anti-inflammatory as well as Pro-inflammatory Activity in Gouty Arthritis.Tregs: Where We Are and What Comes Next?TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling.Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.DOCK8 enforces immunological tolerance by promoting IL-2 signaling and immune synapse formation in Tregs.Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma.Tim-3, Lag-3, and TIGIT.Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity.PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards T-bet and TIGIT.Coming of Age: CD96 Emerges as Modulator of Immune Responses.

P2860

Q30399437-089CB954-9AA0-42E7-9F91-189A46F6161C Q33650505-B9A73D2C-C363-44E3-B5E9-5FB9902B6BE3 Q33731047-798A66D4-A228-41BA-BC6F-1A49FF42F798 Q33814908-0C443BE7-04D5-4AED-B7C8-A60DEFA11D6F Q33909020-D5F6ED6C-59C6-4827-9ABD-74346DE27259 Q36128123-F9BE4CEC-8FD3-439C-A509-38C4EC39575B Q36978175-ADA9236A-9CD9-4958-A522-89F5E751AD71 Q37677433-29A3965F-0F44-4E0F-A2AA-8EB22296DBD7 Q37711827-977DD9C8-BF7A-4EBD-A7C1-E7A3F2DAD249 Q38730989-8ACA4503-3C32-4BB4-B320-6D20C94A019D Q38809776-5F3ECD31-EA48-464B-BC8B-F4CA6CAB471B Q38837469-49BD3698-9420-4E4F-BCA8-8DA354895451 Q38845026-72B68B8B-C44D-4B00-8B23-2431AB52A99E Q38897638-7E82216E-091D-4821-9E72-162621D11B6D Q38988058-E72CEB1B-1A4E-41DD-B98A-A016E795882B Q39062949-C6A78DD1-8917-4F94-9C5D-EFBAEBF505E2 Q39078341-EC9CF1BB-7468-42D1-9266-87E5A4653D7D Q39160992-B66BAFF9-8F0C-471C-9950-8B9BDC79FCA1 Q39454807-63B18443-69C5-4E39-9A97-221FCD3F64AD Q40370455-9CFF3824-E43B-4BEF-A423-539FB8D5ED10 Q40583098-460C9428-4ED1-4394-BC86-23B669C83400 Q44412481-AF639318-7613-4EAF-8D27-F17AAB5EB2BF Q47141380-204560BC-6700-450D-8652-7FB398CC2647 Q47217185-2343B806-4D9C-48DE-84CB-2F758D930A3F Q47271511-8ECC4FA3-256D-4EF5-BFD3-8B22253E36D3 Q47550223-2D6109D6-D93D-4777-9C04-BF43BFF9DCDF Q47863316-0FE8631F-E659-4160-8B18-22D9DF11DF1E Q48273861-E33262D1-2BD3-44C9-8188-372C7BAC9BD3 Q49851572-0B5B4B4E-3A64-47E1-8ADE-F506BE8B633C Q50043938-DCBE623E-CF52-4B01-8EE5-8B97114A0887 Q50125564-FFC3CB5B-DBAA-448A-8DCA-965CCA6F4F50 Q50204340-2A446F67-326C-457D-8E1C-223927EF6536 Q50545420-19EC8043-95B3-42A9-AD29-04626BFA141C Q52676482-94B6DA46-398C-4D1D-B6D8-907CCE4A800F Q52682430-DB0AB555-1575-4A22-B972-BBFC1240C862 Q52689973-84370BA8-BE14-4992-90D7-55B48DF9C06D Q52718461-0DD731B1-3019-46AB-8935-898459603C18 Q54212829-358147D3-4C54-4612-B503-B764469B32AE Q55001208-3027CB9A-B4DE-4508-9847-45E08F3F55B3 Q55026846-04ADBCAF-7DA0-4609-BCDB-BE5A5166FAF6

P2860

TIGIT predominantly regulates the immune response via regulatory T cells.

http://www.wikidata.org/entity/Q36266506

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

TIGIT predominantly regulates the immune response via regulatory T cells.

@ast

TIGIT predominantly regulates the immune response via regulatory T cells.

@en

type

label

TIGIT predominantly regulates the immune response via regulatory T cells.

@ast

TIGIT predominantly regulates the immune response via regulatory T cells.

@en

prefLabel

TIGIT predominantly regulates the immune response via regulatory T cells.

@ast

TIGIT predominantly regulates the immune response via regulatory T cells.

@en

P1433

Q36266506-0F1D4FF3-A5BE-4CA3-B8EF-61DC2CD6C2BE

P1476

Q36266506-00EE6A1A-FA15-49E9-89C0-01271731ED2E

P2093

Q36266506-360E7150-56D3-412D-88D6-5E4E1685F762

Q36266506-7D684B68-77DD-49C7-8A07-C741AC693A0B

Q36266506-7E17534B-DA54-490D-AF58-480EBACE5A14

Q36266506-D599CE5F-962A-448E-8BB8-2DC0FA13E334

Q36266506-E1EB2D46-D8A5-4A50-BFCE-B27CDDE340B6

Q36266506-E8C86FC5-D5C3-499B-A7B8-F75C29811042

P2860

Q36266506-00102E42-4B3E-47F2-86EA-D60BF2C1C6F0

Q36266506-0C20555A-712B-4870-8C1B-B5AB3FADE29E

Q36266506-0C20FF5E-694A-4CCA-8133-C7C23AE5761A

Q36266506-0D945EC5-8355-4992-8DE1-B777426DC187

Q36266506-20D77DA7-0D0F-4DCC-A4D5-0E6CCBD4E032

Q36266506-29572948-50AA-46DC-9127-1044FB0ADBAE

Q36266506-33235164-57C8-42E0-9E62-A58EBF603F11

Q36266506-389943B6-8D17-4BDB-8804-297B940EF8AE

Q36266506-3C63085F-1E4C-4BAD-8645-22C5CBDBF288

Q36266506-44F40322-2BD0-4A6B-A7E0-48AC6B1C844B

P304

Q36266506-DDA19473-87DE-4366-9E2F-D73271B126E0

P31

Q36266506-9CA1A9E5-B952-4720-A680-4C67F8D5E40A

P356

Q36266506-CC1ACF9F-7F36-4EEA-95F9-3E8E21E0FA77

P407

Q36266506-7597839E-26A4-463F-AEB1-38BE48150083

P433

Q36266506-9D99F0A0-993E-493C-991E-847838748CCE

P478

Q36266506-D66ECAE3-C921-47A6-B91D-CA6BA093E694

P50

Q36266506-534C981E-2DE9-4CD4-BF77-DEC1D025A6AF

Q36266506-B98D7424-501B-4E44-BC02-AE8DCC4DD208

Q36266506-BC30317D-BD9C-46E6-B57C-DBE50485C24E

P577

Q36266506-67D09428-C5F9-49E2-AA13-B698A656CAB0

P698

Q36266506-A230B027-A96F-42D3-BF81-91CF655E0EAC

P932

Q36266506-40F95A69-11C2-4DFF-95A4-A8BC802B1F71

P356

P1433

Journal of Clinical Investigation

P1476

TIGIT predominantly regulates the immune response via regulatory T cells

@en

P2093

Ana C Anderson

http://www.w3.org/2001/XMLSchema#string

Dewar J Tan

http://www.w3.org/2001/XMLSchema#string

Kaori Sakuishi

http://www.w3.org/2001/XMLSchema#string

Sema Kurtulus

http://www.w3.org/2001/XMLSchema#string

Shin-Foong Ngiow

http://www.w3.org/2001/XMLSchema#string

Vijay K Kuchroo

http://www.w3.org/2001/XMLSchema#string

P2860

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112)

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

Interleukin-10 determines viral clearance or persistence in vivo

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

The blockade of immune checkpoints in cancer immunotherapy

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

P304

4053-4062

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI81187

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

Michele W.L. Teng

P577

2015-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26413872

http://www.w3.org/2001/XMLSchema#string

P932

4639980

http://www.w3.org/2001/XMLSchema#string